The COVID-19 vaccine developed by Pfizer and BioNTech is likely to protect against more infectious variant of the virus, which was discovered in Britain and has spread around the world. Reuters Emer McCarthy reports. The encouraging results from an analysis of blood of participants in trials are based on more extensive analysis than those released by the drug maker last week. In those tests, Pfizer said a similar lab study showed the vaccine was effective against one key mutation that's found in both of the highly transmissible new variants spreading rapidly across Britain and South Africa. The latest study, which was posted online but is yet to be peer reviewed, was conducted on a synthetic virus with 10 mutations that are characteristic of the variant known as B117 identified in Britain. Among the 11 authors of the study are the co-founders of BioNTech. 辉瑞公司和BioNTech公司开发的新冠疫苗有可能预防更具传染性的新冠病毒变种，该病毒变种是在英国发现的，并已在世界各地传播。请听路透社记者埃默·麦卡锡带来的报道。针对试验参与者血液的分析结果令人振奋，而这一分析结果相较于上周辉瑞/BioNTech制药公司公布的分析结果更为广泛。根据这些试验，辉瑞公司称一项类似的实验室研究表明，其疫苗对一种关键的突变有效，在英国和南非迅速传播的两种高传染性新变种中均发现了这一突变。这项最新的研究已在网上发表，但尚待同行评审，该研究针对英国发现的以结合10种突变为特征的B117新冠变种病毒。这项研究的11位作者中有BioNTech的联合创始人。